Skip to main content

Advertisement

Table 4 Results (Patients with continuous PSA follow up in all 3 intervals)

From: Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir

    SBRT CF-EBRT p-value
   Through year    
# Evaluable patients with PSA 26 37  
Follow-up for All 3 intervals     
PSA measurements     
  Mean (range) 1 3.8 (2 – 5) 4.2 (3 – 11)  
   2 5.8 (4 – 8) 6.6 (4 – 15)  
   3 7.6 (5 – 11) 9.0 (6 – 21) p = 0.03#
Nadir PSA (ng/mL)     
  Median (range) 1 0.81 (0.1 – 2.5) 1.00 (0 – 8.5)  
   2 0.45 (0.1 – 1.4) 0.86 (0 – 2.5) p = 0.02*
   3 0.25 (0.1 – 1.4) 0.70 (0 – 2.2) p = 0.002*
Time to Nadir PSA (mos.)     
  Median (range) 1 12.0 (2.7 – 15.0) 11.5 (1.2 – 15.0)  
   2 22.1 (2.7 – 26.9) 17.9 (1.2 – 26.9)  
   3 31.5 (2.7 – 41.6) 27.4 (1.2 – 41.0) p = 0.02^
Rate of PSA change: ng/mL/month    
  Median slope (range) 1 -0.08 (-0.88, 0.04) -0.09 (-0.60, 0.06)  
   2 -0.06 (-0.38, 0.004) -0.04 (-0.65, 0.05)  
   3 -0.05 (-0.19, 0.001) -0.03 (-0.38, 0.02)  
  1. SBRT: Stereotactic Body Radiotherapy.
  2. CF-EBRT: Conventionally fractionated external beam radiotherapy.
  3. p: Statistical significance.
  4. # The t test was performed to compare the mean number of PSA measurements between the two groups for each interval with means and ranges presented to summarize the results.
  5. ^ The log rank test was used due to compare the time to nadir PSA distributions between the two groups for each interval with medians and ranges presented to summarize the results.
  6. * The Mann–Whitney test was performed to compare the PSA nadir and slope distributions between the two groups with medians and ranges presented to summarize the results.